Breaking News, Collaborations & Alliances

Rigaku and Spera Pharma Partner to Accelerate Pharmaceutical Development

Spera Pharma to use Rigaku’s XtaLAB Synergy-ED for contract analytical services.

Author Image

By: Charlie Sternberg

Associate Editor

Left to right: Keitaro Iwaki, President & Representative Director, Spera Pharma; Jun Kawakami, President & CEO, Rigaku.

Rigaku Corporation, a Group company of Rigaku Holdings Corporation, and Spera Pharma Inc. have initiated a strategic partnership aimed at accelerating and transforming pharmaceutical development by leveraging the two companies’ technologies and expertise. Spera Pharma will use XtaLAB Synergy-ED, an integrated platform for electronic diffraction provided by Rigaku, for contract analytical services, thereby offering customers robust support in pharmaceutical development. The XtaLAB Synergy-E...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters